Sonova (OTCMKTS:SONVY) Upgraded at Morgan Stanley

Sonova (OTCMKTS:SONVY) was upgraded by Morgan Stanley from an “underweight” rating to an “equal weight” rating in a research note issued on Tuesday.

Several other analysts have also commented on the stock. BNP Paribas Exane upgraded shares of Sonova from a “strong sell” rating to a “strong-buy” rating in a research report on Tuesday, March 10th. Jefferies Financial Group lowered shares of Sonova from a “hold” rating to a “moderate sell” rating in a research note on Wednesday, March 18th. Finally, Citigroup restated a “sell” rating on shares of Sonova in a research note on Wednesday, May 13th. Two analysts have rated the stock with a Strong Buy rating, one has given a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy”.

Sonova Price Performance

OTCMKTS:SONVY opened at $47.90 on Tuesday. The company has a quick ratio of 1.43, a current ratio of 1.75 and a debt-to-equity ratio of 0.51. The company has a 50 day moving average price of $48.54 and a 200-day moving average price of $49.94. Sonova has a 1-year low of $42.26 and a 1-year high of $61.09.

About Sonova

Sonova AG (OTCMKTS:SONVY) is a Switzerland-based provider of hearing care solutions, headquartered in Stäfa. The company designs, develops, manufactures and distributes a range of audiological products and related services aimed at improving hearing and communication for people with hearing loss. Its portfolio spans behind-the-ear and in-the-ear hearing instruments, wireless accessories and software solutions that enable connectivity with consumer devices and audiological fittings.

Sonova markets its products under several well-known brands, including Phonak and Unitron for hearing aids, and it is also associated with Advanced Bionics for cochlear implant systems.